UNSPSC 51112525: Trofosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C9H18Cl3N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H64JRU6GJ0, chemically known as 3-(2-chloroethyl)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin 2-oxide but more generally known as trofosfamide, which bears US NIH Compound Identifier 65702. European Medicines Agency schedules Trofosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11331MIG.

UNSPSC 51112525 Trofosfamide is a Commodity code representing a specific chemotherapy agent. State and local governments procure this drug primarily through health and human services agencies and Medicaid programs that manage pharmaceutical benefits for beneficiaries. The recent activity under this code reflects a shift toward direct-to-manufacturer procurement models rather than traditional pharmacy benefit manager channels. State HHS commissions and allied health plans are actively exploring vendor capabilities to establish direct relationships with pharmaceutical manufacturers in order to improve prescription fulfillment efficiency, reduce intermediary costs, and implement value-based pricing or outcomes-based agreements. Vendors responding to solicitations under this code must demonstrate experience in direct contracting with self-insured employers and government health plans, flexibility to negotiate net pricing models outside of rebate structures, and capacity to fulfill product volume requirements through dedicated pharmacy partners or specialized distribution channels.

The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor information on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI represents early-stage market intelligence gathering rather than a formal competitive procurement, with no award value, budget range, or binding timeline specified. The state indicated it would use vendor responses to inform development of detailed procurement specifications and formal RFP issuance. The RFI did not name other recent state or local opportunities under the code, limiting visibility into geographic spread or the prevalence of direct-to-manufacturer procurement models across other jurisdictions at this time.